Belite Bio, Inc. · NASDAQ:BLTE
Belite Bio — Q2 2025 Earnings Presentation
7 slides from Belite Bio's earnings presentation, Aug 11, 2025
Slide 1: Q2 2025 Financial Results Conference Call
Q2 2025 Financial Results Conference Call August 11, 2025, 4:30 p.m. ET Nasdaq: BLTE
Slide 2: Belite Bio Participants
Belite Bio Participants Belite Management Team Tom Lin, MMED, PhD, MBA Hendrik Scholl, MD, MA Nathan Mata, PhD Hao-Yuan Chuang, CFA, MBA, FRM (Chairman, CEO) (CMO) (CSO) (CFO) • 10+ years of executive management • 25+ years of expertise in treating retinal • 15+ years of ophthalmic drug • 13+ years
Slide 3: Forward-Looking Statements and Legal Disclaimer
Forward-Looking Statements and Legal Disclaimer This presentation (including any oral briefing and any question-and-answer in connection with it) is not intended to, and does not constitute, represent or form part of any offer, invitation or solicitation of any offer to purchase, otherwise acquire,
Slide 4: Belite Bio Pipeline Overview
Belite Bio Pipeline Overview PRECLINICAL PHASE 1 PHASE 2 PHASE 3 NDA Stargardt Disease (STGD1) • Ph2, 2-year treatment, showed a statistically significant slowing of lesion growth compared to historical control data • Ph3, 2-year treatment, global trial (“DRAGON” Study) is ongoing (104 subjects, age
Slide 5: Q2 2025 Financial Results
Q2 2025 Financial Results For more info please visit: www.belitebio.com
Slide 6: 2025 Second-Quarter Financial Results
2025 Second-Quarter Financial Results (In thousand USD) For the Three Months Ended June 30 2024 2025 Total operating expenses 10,471 17,596 - R&D 9,078 11,049 - G&A 1,393 6,547 Net loss (9,494) (16,320) • Cash, liquidity fund, time deposits and U.S. treasury bills: $149.2 million • Raised approximat
Slide 7: Q&A
Q&A For more info please visit: www.belitebio.com